Germany's BioNTech identifies first applicable and systemic mRNA cancer immunotherapy vaccine

6 June 2016

BioNTech, a privately-held German biotech, has been credited with finding the first example worldwide of a clinically relevant and systemic mRNA cancer immunotherapy.

Along with its translation research partner TRON (Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz), the company is hailed in the scientific journal Nature for taking a major step towards truly personalized treatment of any cancer.

Entitled Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy, the paper has been published to coincide with the 2016 American Society of Clinical Oncology (ASCO) meeting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK